25-Sep-2026
NUVB highlights nearly 50-month median response as FDA updates IBTROZI label ahead of schedule
Market Chameleon (Fri, 18-Sep 7:41 AM ET)
PRNewswire (Thu, 17-Sep 7:30 AM ET)
PRNewswire (Tue, 15-Sep 8:00 AM ET)
Nuvation Bio to Participate in Upcoming Investor Conferences
PRNewswire (Wed, 2-Sep 4:06 PM ET)
Market Chameleon (Thu, 20-Aug 4:59 AM ET)
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
PRNewswire (Thu, 20-Aug 8:00 AM ET)
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
PRNewswire (Thu, 6-Aug 7:31 AM ET)
PRNewswire (Tue, 4-Aug 8:00 AM ET)
PRNewswire (Wed, 22-Jul 4:05 PM ET)
Market Chameleon (Mon, 20-Jul 7:44 AM ET)
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Nuvation Bio Class A trades on the NYSE stock market under the symbol NUVB.
As of September 25, 2026, NUVB stock price climbed to $5.74 with 2,603,115 million shares trading.
NUVB has a beta of 1.38, meaning it tends to be more sensitive to market movements. NUVB has a correlation of 0.04 to the broad based SPY ETF.
NUVB has a market cap of $2.02 billion. This is considered a Mid Cap stock.
Last quarter Nuvation Bio Class A reported $32 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.05.
In the last 3 years, NUVB traded as high as $9.75 and as low as $.95.
The top ETF exchange traded funds that NUVB belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
NUVB has outperformed the market in the last year with a return of +90.7%, while the SPY ETF gained +18.4%. However, in the most recent history, NUVB shares have underperformed the stock market with its stock returning -1.2% in the last 3 month period and -5.4% for the last 2 week period, while SPY has returned +5.3% and +1.2%, respectively.
NUVB support price is $5.53 and resistance is $5.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUVB shares will trade within this expected range on the day.
